Ralimetinib dimesylate (LY2228820 dimesylate) is the dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities.
Molecular Weight:
612.74
Purity:
99.38%
CAS Number:
[862507-23-1]
Formula:
C24H29FN62CH4O3S
Target:
Apoptosis|||p38 MAPK|||Autophagy
T6047
* VAT and and shipping costs not included. Errors and price changes excepted
